These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

964 related items for PubMed ID: 9300034

  • 21. Hemagglutinating virus of Japan protein is efficient for induction of CD4+ T-cell response by a hepatitis B core particle-based HIV vaccine.
    Takeda S, Shiosaki K, Kaneda Y, Nakasatomi T, Yoshizaki H, Someya K, Konno Y, Eda Y, Kino Y, Yamamoto N, Honda M.
    Clin Immunol; 2004 Jul; 112(1):92-105. PubMed ID: 15207786
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Antigenic properties of a transport-competent influenza HA/HIV Env chimeric protein.
    Ye L, Sun Y, Lin J, Bu Z, Wu Q, Jiang S, Steinhauer DA, Compans RW, Yang C.
    Virology; 2006 Aug 15; 352(1):74-85. PubMed ID: 16725170
    [Abstract] [Full Text] [Related]

  • 27. Effect of partial and complete variable loop deletions of the human immunodeficiency virus type 1 envelope glycoprotein on the breadth of gp160-specific immune responses.
    Gzyl J, Bolesta E, Wierzbicki A, Kmieciak D, Naito T, Honda M, Komuro K, Kaneko Y, Kozbor D.
    Virology; 2004 Jan 20; 318(2):493-506. PubMed ID: 14972518
    [Abstract] [Full Text] [Related]

  • 28. Induction of mucosal and systemic neutralizing antibodies against human immunodeficiency virus type 1 (HIV-1) by oral immunization with bovine Papillomavirus-HIV-1 gp41 chimeric virus-like particles.
    Zhang H, Huang Y, Fayad R, Spear GT, Qiao L.
    J Virol; 2004 Aug 20; 78(15):8342-8. PubMed ID: 15254206
    [Abstract] [Full Text] [Related]

  • 29. A universal T cell epitope-containing peptide from hepatitis B surface antigen can enhance antibody specific for HIV gp120.
    Greenstein JL, Schad VC, Goodwin WH, Brauer AB, Bollinger BK, Chin RD, Kuo MC.
    J Immunol; 1992 Jun 15; 148(12):3970-7. PubMed ID: 1376346
    [Abstract] [Full Text] [Related]

  • 30. Brucella abortus conjugated with a peptide derived from the V3 loop of human immunodeficiency virus (HIV) type 1 induces HIV-specific cytotoxic T-cell responses in normal and in CD4+ cell-depleted BALB/c mice.
    Lapham C, Golding B, Inman J, Blackburn R, Manischewitz J, Highet P, Golding H.
    J Virol; 1996 May 15; 70(5):3084-92. PubMed ID: 8627787
    [Abstract] [Full Text] [Related]

  • 31. Generation of chimeric HBc proteins with epitopes in E.coli: formation of virus-like particles and a potent inducer of antigen-specific cytotoxic immune response and anti-tumor effect in vivo.
    Zhang Y, Song S, Liu C, Wang Y, Xian X, He Y, Wang J, Liu F, Sun S.
    Cell Immunol; 2007 May 15; 247(1):18-27. PubMed ID: 17707782
    [Abstract] [Full Text] [Related]

  • 32. The effect of low-profile serine substitutions in the V3 loop of HIV-1 gp120 IIIB/LAI on the immunogenicity of the envelope protein.
    Peet NM, McKeating JA, de Souza JB, Roitt IM, Delves PJ, Lund T.
    Virology; 1998 Nov 10; 251(1):59-70. PubMed ID: 9813203
    [Abstract] [Full Text] [Related]

  • 33. Papillomavirus virus-like particles can deliver defined CTL epitopes to the MHC class I pathway.
    Peng S, Frazer IH, Fernando GJ, Zhou J.
    Virology; 1998 Jan 05; 240(1):147-57. PubMed ID: 9448699
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Broad recognition of cytotoxic T cell epitopes from the HIV-1 envelope protein with multiple class I histocompatibility molecules.
    Shirai M, Pendleton CD, Berzofsky JA.
    J Immunol; 1992 Mar 15; 148(6):1657-67. PubMed ID: 1371784
    [Abstract] [Full Text] [Related]

  • 36. Induction of anti-HIV-1 immune responses by retroviral vectors.
    Jolly DJ, Warner JF.
    Biotechnol Ther; 1991 Mar 15; 2(1-2):179-93. PubMed ID: 1845120
    [Abstract] [Full Text] [Related]

  • 37. Advances in methods for the production, purification, and characterization of HIV-1 Gag-Env pseudovirion vaccines.
    Hammonds J, Chen X, Zhang X, Lee F, Spearman P.
    Vaccine; 2007 Nov 19; 25(47):8036-48. PubMed ID: 17936444
    [Abstract] [Full Text] [Related]

  • 38. Accell particle-mediated DNA immunization elicits humoral, cytotoxic, and protective immune responses.
    Haynes JR, Fuller DH, Eisenbraun MD, Ford MJ, Pertmer TM.
    AIDS Res Hum Retroviruses; 1994 Nov 19; 10 Suppl 2():S43-5. PubMed ID: 7865332
    [Abstract] [Full Text] [Related]

  • 39. Helper-cytotoxic T lymphocyte (CTL) determinant linkage required for priming of anti-HIV CD8+ CTL in vivo with peptide vaccine constructs.
    Shirai M, Pendleton CD, Ahlers J, Takeshita T, Newman M, Berzofsky JA.
    J Immunol; 1994 Jan 15; 152(2):549-56. PubMed ID: 8283036
    [Abstract] [Full Text] [Related]

  • 40. Anti-idiotypic antibodies to the third variable domain of gp120 induce an anti-HIV-1 antibody response in mice.
    Boudet F, Theze J, Zouali M.
    Virology; 1994 Apr 15; 200(1):176-88. PubMed ID: 7510435
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 49.